Wasting no time making her presence felt on the LPGA Tour, Srixon staffer Rio Takeda, delivered a spectacular performance on ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the ...

Takeda made it rain zebras at a Boston Celtics game Friday. The stunt saw 100 toy zebras parachute from the arena’s rafters ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 V ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Looking ahead, Takeda aims to expand plasma availability, reduce complexity, and improve global patient access to its life-saving treatments. Addressing these challenges is critical, as PDT ...

The Ministry of Food and Drug Safety announced on the 6th that it has granted approval for the rare drug "Prucaclomide capsules (Prucalopride)" imported by Takeda ... 20 in the Global Innovative ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...

Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in adolescents and adult patients with Hereditary ...

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...